Oculis (NASDAQ:OCS) Rating Increased to Strong-Buy at Guggenheim

Oculis (NASDAQ:OCS) was upgraded by stock analysts at Guggenheim to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other analysts also recently weighed in on OCS. Stifel Nicolaus boosted their target price on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Needham & Company LLC raised their price target on shares of Oculis from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, JPMorgan Chase & Co. lifted their price target on Oculis from $38.00 to $42.00 and gave the stock an “overweight” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.38.

Oculis Stock Up 11.1%

Oculis stock opened at $31.00 on Wednesday. Oculis has a 1-year low of $16.00 and a 1-year high of $34.47. The business has a fifty day moving average price of $27.44 and a 200-day moving average price of $24.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -14.55 and a beta of 0.38.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. The business had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.25 million. Equities research analysts forecast that Oculis will post -2.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Oculis

A number of hedge funds have recently bought and sold shares of OCS. Gildi lifeyrissjodur acquired a new stake in Oculis in the fourth quarter valued at approximately $50,250,000. Aberdeen Group plc raised its stake in shares of Oculis by 39.4% during the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after buying an additional 493,827 shares during the period. SR One Capital Management LP lifted its position in shares of Oculis by 98.8% during the 4th quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock valued at $12,801,000 after buying an additional 318,522 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in Oculis in the 4th quarter valued at $9,862,000. Finally, Alyeska Investment Group L.P. increased its holdings in Oculis by 152.3% in the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after acquiring an additional 200,000 shares in the last quarter. Hedge funds and other institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.